Note: Ingredients listed on restricted chemical lists
EC/CAS
1310-73-2
Name of the chemical
sodium hydroxide
Concentration
N/A
EC/CAS
69-65-8
Name of the chemical
D-mannitol C6H14O6
Concentration
N/A
EC/CAS
215-185-5
Name of the chemical
Potassium or sodium hydroxide (20)
Concentration
N/A
EC/CAS
200-711-8
Name of the chemical
D-mannitol C6H14O6
Concentration
N/A
General Information
Revision date
2010-02-18
Product name
DANTRIUM
Chemical name
Not determined
Icons in SDS
Company Information
company name
Pfizer Inc
e-mail address of the competent person responsible for the Safety Data Sheet
pfizer-MSDS@pfizer.com
Section 2
SECTION 2: Hazards identification
Appearance: Pale orange to yellow sterile lyophilized powder
Hazard statements
Non-hazardous in accordance with international standards for workplace safety.
Additional information
Short Term: May cause irritation (based on components) . Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on liver. Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including muscle weakness, dizziness, drowsiness, gastrointestinal disturbances, respiratory depression, liver effects, and crystals in urine (crystalluria). EU Indication of danger: Not classified Australian Hazard Classification Non-Hazardous Substance. Non-Dangerous Goods. (NOHSC): Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
